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Abstract 
The application of nanomagnetic materials to biological 
systems has produced signifi cant advances in research, di-
agnosis, and treatment of numerous pathologies. This chap-
ter summarizes the major applications of magnetic materi-
als: magnetic targeting, drug and gene delivery, magnetic 
separation, the use of magnetic beads in manipulating sin-
gle molecules, as contrast agents in magnetic resonance 
imaging, and for hyperthermia. Biocompatibility require-
ments for magnetic materials used in these applications are 
reviewed.
1. INTRODUCTION
“Nanobiomagnetism” is the intersection of nanomagnetism and medicine 
that focuses on biological systems and/or processes. Magnetism is an inher-
ent facet of life, from iron in blood to the ability of magnetotactic bacteria, 
birds, honeybees and other creatures to navigate by the Earth’s magnetic fi eld. 
Iron plays a critical part in many aspects of human neurophysiology. Natu-
rally occurring iron in the body usually is stored within ferritin, which are 
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12-nm hollow spherical shells that each can hold up to 2,500 iron atoms in 
the form of mineralized ferrihydrite. Anomalous amounts of iron—possibly in 
nanoscale form—are associated with many neurodegenerative disorders such 
as Alzheimer’s, Parkinson’s, and Huntington’s diseases [1].
The ability of magnets to act on objects at a distance makes them valuable 
medical tools. A 1624 report described the extraction of an iron splinter from 
an eye using a magnet [2]. Safety pins, bullets and grenade splinters were re-
moved using magnets [3–5]. Grazing cows are fed magnets to prevent sharp 
metallic objects they eat from damaging the intestines. The invention of stron-
ger, smaller permanent magnets made possible more delicate applications, 
such as temporarily fi xing prosthesis in dentistry, guiding catheters through 
the body, and navigating within the brain [6–8].
Nanoscale materials have a special relevance to biomedical applications 
due to their size compatibility with cells (10–100 μm), viruses (20–450 nm), 
proteins (5–50 nm) and genes (2 nm wide by 10–100 nm long). Nanoparticles 
are small enough to move inside the body without disrupting normal func-
tions, and can access spaces inaccessible by other means. Cells react to the to-
pography of their environment on size scales as small as 5 nm - up to 1000 
times smaller than their own size [9, 10]. Changes in response to topography 
literally can induce growth or death. Nanostructured materials allow study of 
these critical processes on a single-cell level [11].
2. MATERIALS
Magnetic biomaterials have different constraints than materials used for other 
applications. In vivo (in the body) applications require strict biocompatibility. 
In vitro (outside of the body) applications have less strict requirements, but 
techniques involving living cells still must consider the effect of the materials 
on the sample under study. In addition to biocompatibility, materials must be 
capable of being functionalized with one or more molecules, must retain their 
magnetic properties for a reasonable period of time in aqueous media with 
varying pH, must not be cleared too quickly from the bloodstream, and must 
form stable, non-aggregating dispersions [12, 13].
2.1. Biotoxicity
Cells can be killed by external agents or can be induced to “commit suicide” 
via a pattern of events called programmed cell death or apoptosis. Injuries 
from external agents include mechanical damage and exposure to toxic chem-
icals (e.g. chemotherapy). Substances toxic to cells are called cytotoxic, and 
different types of cells can have different responses to the same material.
The vast majority of research in this area involves iron-oxide particles, 
as they are highly biocompatible, cheap, can be made in a variety of ways 
and sizes, and can be made as superparamagnets or ferrimagnets. Iron ox-
ides are metabolized into elemental iron and oxygen by hydrolytic en-
zymes in the body. The iron joins the normal body stores and the body 
compensates by taking up less iron from the stomach. Intravenous injec-
tions of up to 250 mg iron/kg body weight does not produce chronic or 
acute hepatotoxicity in rats [14], while 1–3 mg/kg has been used clinically 
in humans [15].
The disadvantage of iron oxides, however, is their low magnetic suscep-
tibilities. Iron nanoparticles offer an order of magnitude greater suscepti-
bility than iron oxides at room temperature, but are easily oxidized and are 
not as biocompatible as their oxides. Fe-C composite particles made by me-
chanical milling, chemical reduction, or plasmochemical recon-densation 
have been used in clinical trials for hyperthermia and drug delivery [16-18]. 
These particles are biocompatible and the carbon in the particles may assist 
in reversing drug-induced toxicities via physical adsorption. The need for 
monodisperse particles for magnetic recording has stimulated a many chem-
ical methods that produce a broad variety of element and alloy nanoparti-
cles, including Co, Ni, Cu, FePt, CoPt, Fe, CoFe2O4, MnFe2O4, SmCo5 and 
even core-shell particles such as FePt/Fe3O4 [13, 19–27]. Physical deposi-
tion techniques such as inert gas condensation [28–31] and laser ablation 
[32–35] also are used.
2.2. Coatings
Coatings can improve oxidation resistance, colloidal stability, the ability to 
functionalize, phagocyte resistance, mechanical stability, and biocompatibil-
ity. Unfortunately, coating a magnetic nanoparticle with a biocom patible ma-
terial does not necessarily render the nanoparticle biocompatible [36]. The 
chemistry for functionalizing gold is well established and gold coating offers 
corrosion resistance; however, biotoxicity issues may need to be resolved [37, 
38]. Polysaccharide coatings such as dextran, starch, and chitosan are biocom-
patible and offer a range of functionalization options [39–41]; however, they 
can be structurally weak and can be dissolved by highly acidic environments. 
Silicon-based coatings are used to protect particles from lysomal enzymatic 
digestion, and improve mechanical pro perties and chemical stability [42–45]. 
Silica-coating can improve chemical stability, but a porous coating may allow 
the contents inside to be dissolved or oxidized [46, 47].
Many polymers are biocompatible and may be used as coatings for me-
tallic or ceramic particles, or can serve as hosts by either capturing nanopar-
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ticles inside a larger polymer particle or attaching nanoparticles to their sur-
faces. Polyethylene Glycol (PEG) and related polymers covalently bond to 
surfaces or are adsorbed on magnetic nanoparticles and can prolong the circu-
lation time in the bloodstream [39, 40].
2.3. Clearance Time
Particles introduced into the bloodstream are covered rapidly by components 
of the circulation, such as plasma proteins, in a process called opsonization. 
Opsonization makes the particles recognizable to the body’s major defense 
system, the reticuloendothelial system (RES). The RES comprises a diffuse 
system of phagocytic cells (which engulf inert material) that are primarily 
associated with the connective tissues in the liver, spleen, and lymph nodes. 
Macrophage (Kupffer) cells in the liver and macrophages of the spleen and 
circulation are important in removing particles identifi ed by opsonization. A 
signifi cant fraction of nanoparticles can be cleared from the circulation sys-
tem in as little as 15 minutes [48, 49].
The clearance rate is dependent on size, charge, surface hydrophobicity 
and the number and nature of functional groups on the surface [48, 50]. These 
variables are interdependent, making understanding the role of each one inde-
pendently challenging. Some of these variables also may affect the magnetic 
properties. For example, smaller particles more easily evade the RES; how-
ever, the smaller size usually results in a smaller moment.
Anionic particles with negative surface charge have a high affi nity for the 
cell membrane and are typically taken up by the endocytic process [51]. Cat-
ionic magnetite particles show signifi cantly lower cell-survival rates but their 
toxicity depends highly on the magnitude of the surface charge. More highly 
cationic particles tend to be more toxic [52]. Hydrophilic surfaces such as dex-
tran, polyethylene glycol, polyethylene oxide, poloxamers, polysorbates and 
polyoxamines provide a dynamic “cloud” of hydrophilic and neutral chains 
at the particle surface that repel plasma proteins and prevent rapid removal of 
particles from circulation [53–55].
Related to clearance time is the manner in which the nanoparticles attach 
to cells. Nanoparticles can be internalized or remain adhered to the surface. 
The mechanism is determined by the surface charge, adhesion properties, and 
chemical functionality of the cells with respect to the nanoparticle.
2.4. Magnetic Fluids
The delivery of nanoparticles in the human body usually requires suspend-
ing the nanoparticles in a water-based fl uid. In-vitro applications also usually 
require an aqueous environment. Magnetic nanoparticles must remain sus-
pended in fl uid (or be easily re-dispersed when needed) and cannot form ag-
gregates due to van der Waals or magnetic interactions.
Magnetic particles in a solution undergo two types of relaxation:
Brownian relaxation, in which the entire particle rotates, and Néel re-
laxation, in which the moment rotates while the particle remains still. The 
Brownian relaxation time τB is
τB  =  
3ηVH                                                 (1)
                                                                    kT            
where VH is the hydrodynamic volume of the particle, k is the Boltzmann con-
stant, T is the temperature, and η is the dynamic viscosity of the carrier liquid. 
The hydrodynamic diameter characterizes how a particle moves through the 
fl uid in which it is suspended and may be different than the magnetic size due 
to agglomeration, coating, or interactions between the fl uid and the nanoparti-
cle surface [56, 57].
The Néel relaxation time τN is defi ned by [58, 59]
τN = τo exp (∆E / kT )                               (2)
where ∆E is the energy barrier over which the magnetization must reverse, 
and τo ~ 10–9 s.  ∆E usually is determined by the product of the anisotropy K 
and the magnetic volume V : ∆E = KV. Particles with relaxation times faster 
than 100 s are called superparamagnetic. Since ∆E depends on the nanopar-
ticle size as the radius cubed, τN can range easily over 9–10 orders of mag-
nitude. The hydrodynamic and magnetic diameters of the particle can be de-
termined by the peak frequency of the ac susceptibility [57].
The relaxation rates are affected differently by the immobilization of the 
nanoparticles. The Brownian relaxation time can be changed by changing the 
viscosity of the carrier while the Néel relaxation should be independent of the 
carrier liquid. The relaxation rates also are affected differently by phe nomena 
such as immobilization of a nanoparticle due to endocytosis.
3. TARGETING
Some materials are taken up easily by all types of cells, while others are pref-
erentially taken up by specifi c types of cells. A disadvantage to systemic treat-
ment is that healthy cells can be negatively affected, as in chemo therapy. Of-
ten, a specifi c type of molecule needs to be separated for further study, so 
the ability to differentiate between different types of cells is very impor-
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tant. Nanoparticles can be localized by physical, chemical, and/or magnetic 
targeting.
Physical or passive targeting uses surface features of nanoparticles, such 
as hydrophobicity, charge or pH, to induce reactions that cause the nanoparti-
cles to stick to or enter the cells [60]. This mechanism is highly non-specifi c, 
but may be used and to take advantage of the natural clearance of the RES if 
the targeted organs are within the RES [61]. Nanoparticles can be targeted to 
certain pathologies such as tumor or infl amed tissue because of leaky vascula-
ture. This phenomenon is known as the enhanced per meation retention (EPR) 
effect [62].
Chemical targeting uses functionalization of particles to increase the spec-
ifi city of binding [63]. Functionalization is the physical or chemical asso-
ciation of ligands—targeting agents, therapeutics, surfactants, etc.—with a 
magnetic nanoparticle. Functional groups may be incorporated using cova-
lent or non-covalent bonding, and/or physical adsorption. Binding to a recep-
tor of interest is called specifi c binding, while binding to that and other sites 
is called non-specifi c binding. Antibodies, for example, specifi cally bind to 
their antigen, providing an effective means of tagging. Molecules used for 
targeting include proteins, oligonucleotides, antibodies and their fragments, 
lectins, hormones, charged molecules, nucleic acids, peptides, and receptor 
ligands.
Magnetic targeting is used when a therapy has limited ability to be chemi-
cally targeted to specifi c types of cells or tissues due to high non specifi c bind-
ing. The force felt by a magnetic moment of value m in a gradient fi eld is
                                                                                      →            →      →   →Fm = (m · “)B                                          (3)
The magnetic targeting force must compete with the force due to linear 
blood-fl ow rates of about 0.05 cm/s in capillaries to 10 cm/s in arteries and 50 
cm/s in the aorta. Iron-oxide nanoparticles require fl ux densities at the target 
site on the order of 0.1 to 1.0 T with fi eld gradients ranging from 8 T/m (fem-
oral arteries) to over 100 T/m for carotid arteries [39, 64].
The accuracy of magnetic targeting also is dependent on the depth of 
the target tissue within the body: organs such as the liver and the lungs are 
harder to target than organs closer to the surface or in the extremities. The 
primary challenges are producing a focused fi eld of suffi cient magnitude 
and gradient, and fabricating nanoparticles with suffi ciently high moment 
[65]. As an example, magnetic targeting was useful for treating subcuta-
neous mouse lymphoma models, but was not effective in intraspinal glio-
bastoma models [64]. Similarly, permanent magnets are more effective on 
surface tumors and tumors in extremities, while electromagnets or super-
conducting magnets (such as in clinical MRI machines) can be used in loca-
tions requiring higher gradients.
Magnetic targeting has been shown to reduce signifi cantly the movement 
of particles to undesired organs and tissues during the time the magnetic fi eld 
is applied [64]. Micron-sized FeC nanoparticles have been targeted success-
fully to various organs, including the liver, lungs, and the brain [66, 67]. A 
complication is that, in some cases, the particles are retained only while the 
magnetic fi eld is applied. Some studies indicate that the magnetic fi eld pro-
motes extravasation (movement of nanoparticles out of blood vessels) and the 
particles remain in the target area after removal of the fi eld; however, other 
studies show that nanoparticles migrate after the targeting fi eld is removed 
[66, 68–70].
One relatively new approach proposed for magnetic targeting is “ferro-
magnetic seeding” [71–73]. Nano-sized ferromagnetic objects (“dockers”) 
could be inserted by catheter. The docker would reinforce the magnetic gradi-
ent of the external magnetic fi eld, decreasing the need for externally applied 
high-gradient fi elds. A similar idea has been suggested for stents in treatment 
of vascular disease [74–76].
4. MAGNETIC SEPARATION
The detection of specifi c molecules is critical for diagnosis, treatment, and 
prevention of disease. The development of fast, handheld analysis units ca-
pable of detecting multiple species is made more urgent by fears of biolog-
ical and chemical terrorism. Magnetic separation has been applied to every-
thing from separating tin from stainless steel at recycling centers to separating 
pure natural diamonds from diamonds with inclusions of other (magnetic) 
minerals.
Few cells are naturally magnetic enough to be separated due using their 
own inherent magnetism, so the cells must be attached to a magnetic nano- or 
micro-particle with a detectable magnetic moment. Magnetic cell sorting fi rst 
was proposed using surface markers for cell receptors [77]. Magnetic cell sep-
aration allows separation of target cells directly from blood, bone marrow and 
other fl uids in short times due to the fast reaction kinetics. The limiting factor 
for magnetic separation is identifying a linking molecule with high specifi city 
for the desired cell.
Magnetic sorting may be accomplished with micron-sized or nano meter-
sized particles [78]. Smaller nanoparticles produce suspensions that are stable 
against sedimentation due to gravity or an applied magnetic fi eld, while larger 
particles can be used to take advantage of sedimentation as part of the separa-
tion process [79].
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Applications include purging malignant cells from autologous stem cell prod-
ucts [80], water purifi cation [81], minimizing and recycling nuclear waste [82, 
83] and recovering heavy metals [84]. Blood purifi cation using magnetic car-
riers has been used to treat autoimmune and infl ammatory diseases, includ-
ing myasthenia gravis, lupus and Guillain-Barré syn drome [85]. Gram-nega-
tive bacteria, such as E. coli can be detected at con centrations of 15 cfu/mL, 
while gram-positive bacteria such as vancomycin-resistant enterococci can be 
detected at even lower concentrations [86, 87]. T4 and T8 cells in HIV-in-
fected patients have been isolated using magnetic separation, thus allowing 
study of the effect of different drugs on specifi c types of cells [88]. Isolation 
of rare cell populations such as endothelial cells in blood down to 10 cells/ml 
has been accomplished [89].
Magnetic separation consists of three parts: tagging or labeling the desired 
cells with a magnetic marker as described earlier, separating magnetically la-
beled cells from unlabeled cells, and measuring the magnetic properties to 
quantify the number of cells present.
4.1. Separation
Separation may be done in batch or fl ow confi gurations, depending on the 
specifi c application. In batch processing, the magnetic beads and the analyte 
material are mixed. The reaction kinetics determine the amount of time nec-
essary to wait for a suffi cient amount of binding to occur. A magnet is used to 
separate the magnetically targeted cells from the non-targeted cells, as shown 
in Fig. 1. The most commonly used (and commercially available) materials 
for cell separations are micron-sized polymer beads into which a magnetic 
material — usually maghemite — has been embedded.
 Figure 1. A schematic illustration of the magnetic cell separation process.
Fluid-fl ow techniques allow continuous processing and are advancing rapidly 
due to microfabrication capabilities [89, 90]. A permanent magnet can be used 
to either defl ect or collect magnetically labeled particles. Several fl ow chan-
nels may be used in parallel to increase throughput. The magnetic force acting 
on a magnetic carrier is given by [91]:
Fb =  
1  ∆χVH“B2                                                  (4)
                                                              2μo
where Fb is the force on a single magnetic carrier, “B2 is the magnetic energy 
gradient, VH is the hydrodynamic volume of the magnetic carrier, and ∆χ is 
the difference in magnetic susceptibility between the carrier and the suspend-
ing medium. This defl ective force competes with the drag force Fd of the fl uid 
on the particle.
Fd = 3vmDHη                                                      (5)
where DH is the hydrodynamic diameter of the magnetic carrier, vm, is the ve-
locity of the magnetic carrier and η  is the fl uid viscosity.
4.2. Detection
Magnetic sorting techniques have high potential for real-time detection and 
monitoring of bacterial, viral and other pathogenic contamination [92]. Inte-
grated structures utilizing nanolithography can perform sorting and quantita-
tive analysis in a single device. Magnetic transducers have low interference, 
low background signal, do not require sample pre-treatment, and can be small 
enough to be portable. Magnetoresistive techniques have an advantage over 
techniques that use, for example, MFM or AFM tips to manipulate magnetic 
beads attached to molecules, in that they are much faster and have the poten-
tial to detect more than one molecule at a time.
Spin-valve and other magnetoresistive devices detect the stray fi eld from a 
magnetic micro- or nanobead, as illustrated by Fig. 2. Lithographical ly fabri-
cated microcircuits [93–96] may be used to manipulate the magnetic particles. 
Detection limits in the 102 nM can be achieved, and detection of single parti-
cles is theoretically possible.
Detection of multiple species on a single chip is possible by fi xing a 
probe molecule (often DNA) to a polymer layer covering the sensor, as 
shown in Fig. 3. The analyte DNA is a single strand complementary to the 
probe DNA and is labeled (often with biotin). Magnetic microspheres func-
tionalized with streptavidin (which attaches to biotin) are then introduced; 
the microspheres bind to the biotin, which is present only on the success-
fully trapped DNA.
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The signal measured by sensor can be used to quantify the amount of an-
alyte present. The response to the sensor is determined by the in-plane com-
ponent of the stray fi elds induced by the magnetized microspheres. Concen-
trations as low as 3.2 pg/ml have been detected [98]. The introduction of 
tunneling magnetoresistance (TMR) sensing elements and smaller magnetic 
markers will increase the sensitivity of the method.
Figure 2. Sensing the stray fi eld of a magnetic bead using a magnetoresistive sensor 
[93].
Figure 3. Process of detecting DNA via a magnetoresistive device. (After [97] ) The 
probe DNA is fi xed to a polymer layer on the chip (1), the analyte DNA 
tagged with a molecule such as biotin in introduced and allowed to bind (2). 
The excess analyte is removed and a molecule that binds to the biotin (strep-
tavidin) is attached to the magnetic label and introduced (3).
The Bead Array Counter (BARC) was one of the fi rst sensors to measure 
DNA-DNA, antibody-antigen and ligand-receptor pairs at the level of single 
molecules [99–101]. Adapting technology developed for MRAM allows the 
possibility of testing for a large number of different molecules with a single 
chip because different sensors can share circuitry.
A primary challenge in “lab on a chip” devices is to integrate the fl uidics and 
the sensing devices on a scale that allows a handheld device [102]. A microfab-
ricated chip comprising a compact electromagnet, a GMR sensor and a micro-
fl uidic fl ow cell that can simultaneously detect eight different analytes and is 
small enough to sit on a table top already has been developed [103]. More re-
cently, a planar Hall effect magnetic sensor using exchange-biased Perm alloy 
has been shown capable of detecting a single 2-micron magnetic bead, which 
corresponds to a 300 nV signal at 10 mA and 15 Oe applied fi eld [104]. The ad-
vantage of planar Hall sensors is that the entire active surface is used for bead 
detection, in contrast to GMR or spin-valve sensors. A higher signal-to-noise 
ratio is expected, and the lower noise of the planar Hall sensors is expected to 
make detection of single nanobeads possible [105]. Magnetic tunnel junctions 
and anisotropic magnetoresistive rings are also possible candidates.
An alternative detection technique for biological molecules is based on 
changes in the Brownian relaxation due to binding [106, 107]. The relaxation 
frequency of a nanoparticle changes when it binds to another molecule, as 
the binding increases its hydrodynamic size. The shift is proportional to the 
hydrodynamic size of the nanoparticle, allowing discrimination between tar-
get molecules with different sizes (although molecules with different func-
tionalities, but similar sizes cannot be independently detected). An advantage 
of this technique is a signal is present both before and after binding, which al-
lows for reliability checks.
Superconducting Interference Device (SQUID) sensors are more sensitive 
than GMR devices, but require low temperatures and magnetic shielding. RF 
Squids have been used to measure magnetic markers to which monoclonal an-
tibodies have been attached [108]. SQUID sensors also can be used to detect 
changes in relaxation due to binding or changes in local environment. Mag-
netic nanoparticles immobilized in vivo, homogeneously distributed over a to-
tal volume of 0.1 ml, could be detected at a limit of 0.3 nmol using a SQUID 
gradiometer [109, 110].
5. MAGNETIC TWEEZERS
Magnetic beads can provide a “handle” that can be used to manipulate mol-
ecules and investigate intermolecular interactions [111]. DNA strands can be 
attached to a glass surface on one end and a micron-sized magnetic bead on 
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the other. Magnetic fi elds can be used to apply linear or torsional force to the 
DNA, allowing investigation of the extension and elasticity of the molecule 
using forces from fN to a few tens of pN [112–115].
Mechanical manipulation is interesting because cell morphology regulates 
many functions, including cell growth, proliferation, protein synthesis and 
gene expression; however, there is much to be understood about how mechan-
ical signals are translated into biological processes. Magnetic twisting cyto-
metry can be used to apply controlled mechanical stresses directly to specifi c 
cell-surface receptors via ligand-coated particles. Cellular mechanical proper-
ties such as cell stiffness and viscosity can be measured in this manner [116–
118]. The reliability of these measurements, however, can be affected by how 
the magnetic bead binds to the cell. Although nanoparticles may localize at 
a cell-membrane receptor and remain external to the cell, most nanoparti-
cles are taken into the cell via receptor-mediated endocytosis, which can pro-
duce an inhomogeneous cell shape. Applied forces and torques may not be as 
evenly distributed across these regions and a shear stress may result. The in-
ternalization of magnetic nanoparticles by cells can, however, allow probes of 
the cell interior. Anionic ferromagnetic nanoparticles can be internalized by 
endosomes via endocytosis, producing a superparamagnetic endosome. The 
magnetized endosomes elongate in the fi eld, allowing study of the rheological 
properties of the cell interior [119,120].
6. DRUG AND GENE DELIVERY
Controlled drug delivery has the potential to improve drug effi cacy, as well 
as patient convenience and compliance [121, 122]. Although overall drug 
dosage can be reduced by 50–80%, dosage at the target site is increased and 
systemic uptake is decreased. Local drug delivery also reduces the patient-
to-patient pharmacokinetic variability inherent in oral and intravenous appli-
cations. Protecting the drugs until they reach their target area increases the 
usability of drugs that have a short half-life in the body. Allowing the release 
of a drug over a prolonged period of time maximizes the effect of drugs such 
as chemotherapeutics that are effective only during a specifi c part of a cell’s 
life cycle.
Nanoparticles were fi rst used for drug delivery starting around 1970, when 
they were developed as carriers for vaccines and anticancer drugs, and are 
now widely used [123–125]. The ideal nanoparticle for drug delivery must be 
able to effi ciently incorporate a reasonably high weight fraction (loading) of 
the drug, must form a stable suspension in an aqueous medium, must be bio-
compatible and biodegradable, and must not be cleared too rapidly from the 
bloodstream. In addition, nanoparticles should be able to be made in a range 
of sizes, but with uniform size distribution, and should be able to be further 
functionalized. The main attraction of magnetic nanoparticles from the per-
spective of drug delivery is the ability to use the magnetic properties to either 
limit the drug to a particular region using magnetic targeting, or to release the 
drug remotely.
Drug may be encapsulated in, conjugated to, or adsorbed onto the surface of 
a nanoparticle. The drug may be released via degradation of the carrier parti-
cle or may be triggered by heat or pH. Many drug delivery systems use polylac-
tic-co-glycolic acid (PLGA), polycaprolactone (PCL) and their copolymers, as 
these are biodegradeable, FDA-approved materials and the degradation rate can 
be controlled by the particle formulation [126]. Careful choice of surfactants 
can allow hydrophobic drugs to be transported throughout the body [127].
Ionically bound pharmaceuticals have the advantage that the active-low-
molecular weight substances can desorb from the carriers after a defi ned time 
span and diffuse from the vascular wall into the tissue. The diffusion through 
the vascular wall can signifi cantly change the desorption kinetics of the phar-
maceutical [128]. Epirubicin chemoadsorptively bound to a polymer-coated 
particle can desorb according to physiological environment (pH, osmolarity, 
and temperature) [129]. The half-life of the drug desorption can be fi xed to be 
approximately the same as the desired time for magnetic fi eld targeting.
6.1. Chemotherapy
Cancer is a leading cause of death worldwide. Chemotherapy, a common 
treatment, is non-selective and causes signifi cant negative side effects. Che-
motherapy dosages are calculated primarily by the individual tolerance lev-
els of a particular patient, which means that physically weaker patients are not 
able to receive adequate doses for successful treatment [122]. Targeting the 
drugs and preventing release until they reach the tumor decreases the damage 
to normal cells and increases the dosage at the tumor.
The fi rst evidence for the utility of nanospheres in cancer treatment was 
demonstrated in the early 1980s. Widder, et al. showed signifi cant remission 
of Yoishida sarcoma without drug toxicity in rats using magnetically targeted 
albumin microspheres with doxorubicin [69, 130, 131]. The majority of mag-
netic nanoparticles used for drug delivery are based on iron-oxide or iron-car-
bon combinations. Mitoxantrone, doxorubicin, mitomycin C, etoposide, pa-
clitaxel, oxaliplatin and epirubicin have been bound to iron oxide or Fe-C 
fl uids for magnetically targeted cancer treatment [16–18, 39, 67, 69, 131, 132]. 
MTC™ is a micron-sized Fe-C particle with 3–10 times greater susceptibil-
ity than the corresponding-sized Fe3O4 particles [133]. The high susceptibility 
is necessary for the goal of magnetically targeting hepatocellular (liver) carci-
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noma, which requires the particles to be captured at depths up to 14 cm. De-
spite the recent suspension of one U.S. Phase II/III liver-cancer trial that was 
using magnetically targeted Fe-C particles, other studies suggest high poten-
tial for treatment of cancer in humans.
6.2. Radionuclide Therapy
Radiotherapeutics attack cancer by causing radiation damage to DNA in cells. 
The requirements differ from those for drug delivery because the radiother-
apeutic can act at a distance and does not have to separate from the delivery 
particle. Radiotherapeutics can be selected to provide action over a range of 
distances, from tens of nanometers to hundreds of microns. Three radiother-
apy modalities can be identifi ed. Brachytherapy, most often used with beta-
emitters, uses tightly enclosed radioactive material that is brought in close 
proximity to the tumor. A second modality is intravenous injection so that the 
radiopharmaceutical binds to the outside of the tumor cells or is taken up by 
the cell and irradiates from within. The third approach uses a carrier loaded 
with the radiotherapeutic that is transported to the vicinity of the target cells, 
and then released.
Y-90 is a stable beta emitter, releasing less than 5% of the bound radioactiv-
ity within 3 weeks [134, 135]. The polymer decay rate can be matched to the 
64.1-hour half-life, so that once the particles loose a signifi cant amount of their 
radioactivity, they decay into lactic acid. This treatment could deliver up to 100 
times greater dose of radiation to the tumor than conventional external beam 
radiation therapy and minimize the damage to healthy tissue [135, 136]. Squa-
mous cell carcinoma in rabbits has been treated using 100-nm multidomain 
magnetic iron oxide/hydroxide particles onto which I123 has been ionically 
bonded [137, 138]. A permanent magnet is used for magnetic targeting and the 
biodistribution of the ferrofl uid is detected using a gamma camera [138].
6.3. Magnetic Switches
Magnetic fi elds can be used to activate the release of a drug remotely. For 
example, liposomes can be made to encapsulate magnetic nanoparticles 
and drugs. An applied ac fi eld causes the magnetic particles to heat, which 
in turn opens the lipid layer and releases the encapsulated drug [139, 140]. 
A similar effect can be used with thermoresponsive gels, which are chemi-
cally cross-linked polymer network characterized by pores, elasticity, and the 
ability to change volume when stimulated by temperature. Entrapping mag-
netic nanoparticles in the gel allows control of the pore size via the external 
ac magnetic fi eld. Drug entrapped in the pores is released when the gel swells 
and the pores expand [141, 142].
Magnetically induced stress has been used to control drug release. Polymer 
spheres fi lled with magnetic nanoparticles and drug subjected to an oscillat-
ing magnetic fi eld produced small stress-induced cracks in the polymer. The 
cracks allowed liquid to enter the spheres and carry out drug. Using magne-
tism as a “release-on-demand” mechanism could be useful for insulin-depen-
dent diabetics [143, 144].
Innovent, Inc. has developed a magnetic capsule made of two or more 
parts that are held together magnetically. Demagnetizing the magnetic capsule 
by applying alternate pulses of opposite magnetic polarity allows the capsule 
to open. The resulting capsule parts are small enough for the patient to elim-
inate. The capsule is smaller than ones now used for endoscopy and could be 
used for delivery of drugs to the gastrointestinal tract [145].
6.4. Gene Delivery
Transfection refers to the incorporation of exogenous DNA into a cell; how-
ever, the incorporation process is diffusion limited and thus slow. “Magne-
tofection” uses magnetic targeting of polyethylenimine-coated magnetic 
nanoparticles to which gene vectors are electrostatically attached. The mag-
netic targeting overcomes the limitations of diffusion, allowing increases in 
uptake in the target tissue [146–148]. Research remains to be done on the in-
fl uence of the externally applied magnetic fi eld beyond merely attracting the 
nanoparticles to the tissue. Magnetic targeting also has been used to deliver 
stem cells [149].
7. MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging (MRI) aids in diagnosis, research, and treatment 
of a wide variety of pathologies. The fi rst attempts to use nuclear magnetic 
resonance for medical purposes were made by Odeblad and Lindstrom in 
1955 [150], but it was not until 1973 that Lauterbur developed magnetic-fi eld-
gradient methods capable of generating images that could be used clinically 
[151]. Although hydrogen atoms are the usual targets, magnetic nuclei such 
as 13C, 19F, 23Na and 31P can be detected in biological tissue. MRI measures 
change in the magnetization of the protons in water molecules in a magnetic 
fi eld after being subjected to a radio-frequency magnetic fi eld pulse. Protons 
in different types of tissues relax differently, thus providing the contrast nec-
essary to distinguish between different types of tissues.
One mm3 of water contains 6.7 x 1019 H nuclei. The nuclear magnetic mo-
ment of the sample is proportional to the magnetic fi eld strength and inversely 
proportional to temperature and an external magnetic fi eld creates a surplus 
476                   LESLI E-PELECK Y,  LA B H A SETWA R,  & KRAUS (2006) NANOBIOMAGNETICS                                      477  
of nuclear spins aligned parallel to the fi eld. The surplus in room-tempera-
ture water at a magnetic fi eld of 1 T corresponds to a fraction of 3.2 × 10–6 of 
the protons. A radio-frequency fi eld at a frequency near the Larmor frequency 
stimulates precession of the nuclear magnetization about the static fi eld. The 
amplitude of the processing nuclear magnetization decays with time until the 
original equilibrium state is recovered.
Two time constants describe the relaxation process: T1 is the longitudinal 
relaxation time (a spin-lattice relaxation involving energy transmission to the 
surroundings) and T2 is the transverse relaxation time (a spin-spin relaxation). 
An individual moment sees many other moments in thermal (Brownian) mo-
tion and thus experiences a continuously changing magnetic perturbation fi eld. 
Spectral components of the fi eld that correspond to the Larmor frequency in-
duce longitudinal relaxation, while transverse relaxation is due to the frequency 
of collisions between the molecules [152]. The slope of the inverse relaxation 
time vs. concentration plot is called the relaxivity, with r1 being the relaxiv-
ity corresponding to T1 relaxation and r2 being the relaxivity corresponding to 
the T2 relaxation. Fat has a very effi cient energy exchange and thus a short T2, 
while water is less effi cient and has a longer T2. The white matter of the brain 
has a T2 around 60–100 ms and a T1 an order of magnitude larger.
Magnetic contrast agents work by changing the relaxivity of the water in 
the area near the contrast agent, thus improving differentiation between oth-
erwise similar types of tissue. Individual atoms such as Gd and Fe decrease 
T1 by orders of magnitude; however, they must be chelated for in vivo use to 
prevent toxicity. A disadvantage of these types of contrast agents is that they 
equilibrate rapidly throughout the interstitial space, making it diffi cult to iden-
tify specifi c regions with high precision [153]. Superparamagnetic nanoparti-
cles, either coated metal particles or polymeric nanoparticles loaded with metal 
atoms, preferentially affect the transverse relaxation time T2 as protons diffuse 
within the inhomogeneous magnetic fi eld created by the magnetic clusters.
Most clinically used nanoparticle contrast agents are iron-oxide based 
and are grouped into two categories: Superparamagnetic iron oxides (SPIOs) 
are between 500 nm and 50 nm, and ultra-small SPIOs (USPIOs), which are 
smaller than 50 nm.
SPIOs are used for gastrointestinal tract, liver, and spleen imaging and take 
advantage of the natural clearance of the RES, the transit time through the gut 
or preferential uptake by specifi c cells. The most promising uses of SPIOs are 
to improve the sensitivity of detection and localization of primary and meta-
static brain tumors, infl ammation and ischemia (insuffi cient supply of blood 
to an organ) [ 154–156].
USPIOs can be used as “blood pool agents” because their smaller size al-
lows them to remain in the bloodstream for longer times. They can be used to 
assess perfusion (the passage of blood into an organ or tissue) in areas of isch-
emia and provide information about capillary permeability. They also can be 
used to study the extent of tumor neovascularity and associated permeability 
changes [153].
Nanoparticle T1 contrast agents are being studied as well. Gd-chelates can 
be surrounded by a polymer with a high affi nity for the metal and again by a 
porous hydrophobic polymer shell that modulates access to the core [157]. 
The coatings increase the circulation time, which has been the primary limi-
tation of Gd chelates. When administered intravenously, the nanoparticles re-
main in the intravascular space, and thus provide excellent visualization of the 
vasculature.
Natural targeting can be used by incorporating magnetic nanoparti-
cles within the lipid phase of liposomes. The relaxivities of magnetolipo-
somes vary enormously, depending on size and surface characteristics, and on 
whether the magnetoliposomes are free or bound [139]. Changes in the relax-
ivity can indicate bound vs. unbound magnetoliposomes and even changes in 
the ratio r1/r2 also can be used for contrast.
Magnetic contrast agents can be targeted; however, targeting is usually 
chemical due to the magnetic nature of the resonance measurement. Reste-
nosis, a complication of coronary angioplasty that involves the pro liferation 
and migration of vascular smooth muscle cells, and arterial plaques can be de-
tected by targeted Gd contrast agents [158]. The acoustic refl ectivity increases 
when the nanoparticles are bound, thus allowing high contrast between the 
targeted tissue and the background. MRI also can be used to confi rm the tar-
geting of drug-delivery nanoparticles [159].
MRI resolution can be 20–25 pm, which means that real-time tracking of 
single cells is possible if a cell can be loaded with suffi cient magnetic material 
[160]. These techniques are useful in understanding how cells migrate in re-
sponse to diseases. Biocompatible magnetic nanosensors have been designed 
to detect molecular interactions in biological media via MRI. Changes in re-
laxation times due to the nanoparticles binding with the target molecule are 
detected by MRI contrast, thus allowing simultaneous study of the location 
and chemical functionality of specifi c types of cells. These magnetic nanosen-
sors can detect specifi c mRNA, proteins, enzymatic activity, and pathogens 
with sensitivity in the low femtomole range (0.5–30 fmol) [161–163]. Other 
applications include imaging gene expression [164, 165].
Work is in progress on chip-scale integration for MRI of very small sam-
ples. Micromechanical cantilever oscillators allow for high sensitivity mag-
netic measurements [166].  Integrating DC and RF magnetic fi eld sources into 
such a chip would allow for magnetic resonance measurements with signifi -
cantly improve sensitivity.
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8. HYPERTHERMIA
Cancer growth is slowed or stopped at temperatures in the range of 42–48 °C, 
while normal cells can tolerate even higher temperatures [167, 168]. Heat 
treatments can be characterized as hyperthermia, in which the temperature is 
limited to less than about 50 °C, and thermal ablation, which involves higher 
temperatures.
Hyperthermia induces almost reversible damage to cells and tissues; 
however, it can enhance radiation and chemotherapy injury of tumor cells 
[169]. The enhancement is attributed to heat-induced malfunction of the 
processes that ordinarily repair DNA. Hyperthermia also affects the activity 
of regulatory proteins, kinases and cyclins, which in turn alters cell growth 
and differentiation, and can induce apoptosis. Thermoablation produces ne-
crosis, coagulation or carbonization that could be suffi cient to eliminate the 
need for radio- or chemo-therapy [68, 170]. Thermoablation has been stud-
ied primarily for diffi cult-to-treat cancers (such as liver cancer) with lim-
ited treatment options, and for areas of the body far away from vital organs 
(e.g. breast cancer). Targeting of the magnetic nanoparticles to specifi c sites 
eliminates the systemic side effects that result from oncologic treatments 
(i.e. nausea or radiation pneumonitis); however, whole body hyperthermia 
produces non-selective damage and thermal ablation has a higher risk for 
collateral damage.
Hyperthermia and thermoablation have been accomplished using capac-
itive or inductive coupling of rf fi elds (10–100 MHz), microwaves (> 300 
MHz), ultrasound, lasers or external heat [171–177]. Macroscopic metal im-
plants of Cu and other high-conductivity metals have been used to induce 
eddy-current heating. The absorbed power per mass is called the specifi c ab-
sorption rate (SAR), which can be expressed as
SAR = 
∆Q Á 1  ˜                                                    (6)
                                                      ∆t È mf ˘
where ∆Q is the energy converted into heat. ∆t is the time over which the con-
version occurs, and mf is the magnetic material mass [170]. The SAR is deter-
mined by the “rate-of-temperature-rise” method [178]
SAR = c dT                                                              (7)
                                                      dt
where c is the specifi c heat and dTldt is the rate of temperature change. The 
density of absorbed power is related to the SAR by      
P = SAR  
mf
                                                 (8)
                                                              
V
The coupling of an external RF magnetic fi eld to magnetic particles in the 
body results transfer of energy to the tissue by: 1) eddy current heating, 2) 
hysteretic heating: heat generated when a magnetic material is forced around 
part or all of the hysteresis loop, 3) viscous heating: heat generated by the ki-
netic motion of a particle within a viscous fl uid, and 4) magnetic resonance. 
The loss power of the magnetic particles should be as high as possible so as to 
allow the lowest possible dose [179].
Avoiding neuromuscular electrostimulation requires frequencies greater 
than 50 kHz, and the penetration depth limits the frequency to less than 5–
10 MHz, effectively eliminating effects from magnetic resonance [180]. 
Typical values used with iron-oxide nanoparticles are magnetic fi elds of fre-
quency in the range 50–500 kHz and amplitude 1–15 kA/m [170, 181]. Jor-
dan suggests that materials should be investigated for use at frequencies 
near 100 kHz so as to optimize the SAR in the magnetic material in com-
parison to the potential SAR in tissues due to eddy currents [182]. For ther-
mal ablation, a frequency of 400 KHz and 6.5 kA/m should be tolerable for 
the exposure of parts of the body with diameters of up to 15 cm, if short ex-
posure times are used [170, 183]. In many nanoparticle systems, the SAR is 
best be described by
SAR = kf nH2                                             (9)
where n ranges from 1.1 to 1.5, suggesting that there must be a frequency-
dependent process of magnetic relaxation that accounts for the changes in 
the power n [180]. Theoretical predications for Rayleigh loops suggest a H3 
dependence.
Modeling magnetic hyperthermia is diffi cult due to the complex magneti-
zation reversal mechanisms found in nanoparticles. Optimization of nanopar-
ticle properties is important to limit the amount of material that must be intro-
duced. The SAR achievable for a given combination of fi eld, frequency, and 
type of particle usually must be determined experimentally. SAR values range 
from a few W/g to a few hundred W/g for optimized values (i.e. using the 
fi eld and frequency that provides the best results for the particular system be-
ing studied) [167]. The SAR depends on many factors, including the effect of 
coating on surface spin dynamics, the effect of surface properties on Brown-
ian relaxation, size, and crystallinity among other factors.
480                   LESLI E-PELECK Y,  LA B H A SETWA R,  & KRAUS (2006) NANOBIOMAGNETICS                                      481  
The SAR due to losses along a hysteresis loop is:
SARhyst = 
vμ0 f ○ÛHdM                                              (10)                                                   mf   
Magnets with large-area loops are thus preferred for hysteresis hyperthermia; 
however, the size of the magnetic fi eld at the location of the nanoparticles 
may be limited, making only minor loops accessible.
In macroscopic implants, shape anisotropy can be used to maximize the 
area of the loop; however, local heating (“hot spots”) is a concern. In nanopar-
ticles, overcoming the energy barrier to rotation of the magnetization (with 
the particle fi xed) determines the properties of the loop. Ferromagnetic parti-
cles much larger than the superparamagnetic limit have no implicit frequency 
dependence to the hysteresis in the frequency range considered. The physi-
cal basis of the heating due to superparamagnetic particles shows that the fre-
quency dependence is more important than for their ferromagnetic counter-
parts [184].
The use of iron oxides for hyperthermia of tumors was fi rst proposed by 
Gilchrist et al. [185]. Magnetic nanoparticle hyperthermia has a potential ad-
vantage over radio- and chemo- therapies because there is no systemic buildup 
in organs, so larger doses are possible. The nanoparticles can be introduced 
into the body once, and then used for multiple treatments. Nanoparticles can 
be magnetically targeted, injected directly into the tumor in some cases, or in-
jected into the vasculature supplying the tumor. Chemical and/or magnetic tar-
geting help limit side effects [186]. Tumors derive their nourishment from the 
supplying vasculature, so blocking the blood supply via magnetic nanoparti-
cle thermoablation has been attempted [187–189].
The fi rst clinical human trials using magnetic hyperthermia were reported 
by Lubbe, et al. [70, 129, 137, 190] who used 100-nm starch-coated iron-ox-
ide particles bound with epirubicin for treatment of advanced solid cancers. 
Jordan recently reported positive results from ongoing trials of advanced can-
cer patients who received magnetic nanoparticle hyperthermia in conjunction 
with conformal external beam radiation therapy [191]. The therapy was well 
tolerated by the patients and signifi cant increases in the length and quality of 
life were observed.
The greatest challenge to the effi cacy of hyperthermia using magnetic 
nanoparticle fl uids is balancing the rate of thermal energy deposition with the 
mechanisms responsible for thermal dissipation. Modeling heating is com-
plex due to the multiple factors affecting temperature change, including tis-
sue density, amount of fat, and blood fl ow. Tumors in highly perfused organs, 
such as the kidney, lung and liver, are harder to heat due to the high blood 
fl ow [68, 170]. The dependence of temperature rise on distance is steep, and 
there are delays in heating and cooling after the fi eld is applied or removed. 
Larger bones, such as the pelvis and skull shield tissues and produce inho-
mogeneous heating. Non-uniformity of tumors also poses a complication, as 
large tumors heat at a greater rate than small tumors due to the poorer tissue 
cooling and differences in heat conduction in the necrotic regions of large tu-
mors [167, 192, 193].
One approach to controlling temperature is to use materials with a Cu-
rie temperature between 42 and 50 °C, as these materials automatically “turn 
off ” when the temperature becomes too high. Substituted ferrites such as 
(Co1–xZnx)Fe2O4, manganates such as La1–xMexMnO3 [Me=Sr, Ba, Pb, Ag, 
Na] and substituted yttrium-iron garnet Y3Fe5–xAlxO12 are ideal candidates due 
to their stability against oxidation (relative to metals) and the ability to tune the 
Curie temperature by composition [56, 194, 195]. Ni-Cu and Ni-Pd alloys have 
been investigated, but biocompatibility issues must be addressed [196–200].
9. OTHER APPLICATIONS
Magnetic nanoparticles can be used simultaneously for more than one of the 
applications discussed; for example, MRI can be used to confi rm magnetic 
nanoparticle distribution prior to using the same particles to administer hyper-
thermia [201]. A combination of fl uorescence and magnetic-nanoparticle-en-
hanced MRI was used for preoperative magnetic resonance imaging and as 
an intraoperative optical probe during surgery, allowing clearer delineation of 
brain tumors. These “multimodal nanoparticles” may allow radiologists and 
neurosurgeons to see the same probe in the same cells and thus improve iden-
tifi cation of tumor margins [202, 203]. A nanoparticle combining near-infra-
red fl uorescent dye with magnetism allows the particles to be located by MRI 
while the fl uorescent dye provides simultaneous information about the molec-
ular environment about the nanoparticle [204].
Although most applications try to avoid agglomeration, the intentional for-
mation of a blockage of magnetic nanoparticles to block blood supply to a tu-
mor has been investigated [67, 70, 137]. Aggregation and selective uptake has 
been used to destroy cells via the application of pulsed magnetic fi elds and 
subsequent rupture of cells [205].
Retinal detachment is a major cause of vision loss in adults. The usual treat-
ment is the scleral buckle, which is a silicone band sewn to the outside of the 
eye that compresses the wall of the eye inward to close the holes in the retina. 
Sterically stabilized 4–10 nm magnetic particles in a poly(dimethylsiloxane) 
biocompatible fl uid can be held in place with an external magnetized scleral 
buckle, thus providing a stable internal blockage that encircles the entire eye 
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periphery with a ring of silicone oil. No fl uid contacts the central vitreous 
cavity or the lens, thus decreasing the chances of undesired contact and/or 
damage [56, 206].
Many neurodegenerative diseases indicate the disruption of normal iron 
homeostasis in the brain. Recent experimental work indicates that nanoscale 
magnetic biominerals (primarily magnetite and maghemite) may be associated 
with senile plaques and fan fi laments found in brain tissue affected by these 
diseases. Understanding the role of iron in neuro degenerative disease could 
help understand the origin, diagnosis and treatment of these diseases [175].
10. CONCLUSION
The fi eld of nanobiomagnetics is exceptionally broad, involving researchers 
from medicine, pharmaceutical science, chemistry, physics, biology, engineer-
ing, and materials science. The literature is similarly decentralized, making it 
impossible not to omit some contributions in this article. Recent reviews men-
tioned in this chapter provide additional information for the reader interested 
in more detail on a specifi c topic. Nanomagnetics researchers have much to 
contribute to this new and exciting fi eld.
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